- Home
- INCY vs WES Comparison
INCY vs WES Comparison
Compare INCY & WES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INCY | WES |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 16.3B |
| IPO Year | 1993 | 2008 |
Fundamental Metrics
Financial Performance| Metric | INCY | WES |
|---|---|---|
| Price | $94.72 | $39.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 5 |
| Target Price | ★ $94.94 | $41.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 9.24% |
| EPS Growth | ★ 3878.02 | N/A |
| EPS | ★ 5.90 | 3.38 |
| Revenue | ★ $4,813,105,000.00 | $3,740,425,000.00 |
| Revenue This Year | $19.59 | $8.40 |
| Revenue Next Year | $10.88 | $6.96 |
| P/E Ratio | $16.02 | ★ $11.66 |
| Revenue Growth | ★ 18.09 | 5.81 |
| 52 Week Low | $53.56 | $33.60 |
| 52 Week High | $109.28 | $43.33 |
Technical Indicators
Market Signals| Indicator | INCY | WES |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 55.40 |
| Support Level | $94.28 | $38.55 |
| Resistance Level | $96.89 | $40.57 |
| Average True Range (ATR) | 3.13 | 0.70 |
| MACD | -1.42 | -0.05 |
| Stochastic Oscillator | 12.65 | 49.51 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.